To evaluate the ability of SYNE1 mutation to served as a biomarker predictive of the clinical response to ICB therapy, we analyzed datasets from patients with stage 4 ccRCC using the TIDE algorithm. This evidence concerns the gene SYNE1 and nonpapillary renal cell carcinoma.